Cleidocranial dysplasia with growth hormone deficiency: a case report
Open Access
- 16 January 2020
- journal article
- research article
- Published by Springer Science and Business Media LLC in BMC Pediatrics
- Vol. 20 (1), 1-4
- https://doi.org/10.1186/s12887-020-1914-8
Abstract
Background Cleidocranial dysplasia (CCD) is a rare skeletal disorder with autosomal dominant inheritance that is characterized by hypoplastic clavicles, delayed closure of the cranial sutures, dental abnormalities, and short stature, among other features. The responsible gene for CCD is RUNX2 located on the short arm of chromosome 6p21. In general, there are intrafamilial variations in height among CCD patients. Few studies have reported data on recombinant human growth hormone (rhGH) treatment for patients with CCD; thus, it remains to be elucidated whether rhGH treatment can improve short stature. Here, we report a case of a 6-year-old girl with CCD who has growth hormone deficiency (GHD) and a novel mutation of RUNX2. Case presentation At 5 years of age, this patient was diagnosed with GHD and rhGH treatment was initiated. Thereafter, she was diagnosed with CCD due to the presence of hypoplastic clavicles and an open fontanelle, which was also observed in her mother and brother. She responded well to rhGH treatment; her height improved from - 3.2 SD to - 2.4 SD after 13 months. Conclusion A detailed patient history and physical examination are necessary for the early diagnosis of CCD. Similarly, to ascertain the effect of rhGH treatment, careful evaluation of the patient's final height post-therapy is needed.This publication has 12 references indexed in Scilit:
- Clinical, radiological, and auxological characteristics of patients with cleidocranial dysplasia followed in a pediatric referral hospital in ArgentinaArchivos Argentinos de Pediatria, 2018
- Cleidocranial dysplasia: Clinical, endocrinologic and molecular findings in 15 patients from 11 familiesEuropean Journal of Medical Genetics, 2017
- The response to growth hormone treatment in prepubertal children with growth hormone deficiency in Japan: Comparing three consecutive years of treatment data of The Foundation for Growth Science in Japan between the 1990s and 2000sEndocrine Journal, 2017
- Promotion of Osteoblast Differentiation in Mesenchymal Cells Through Cbl-Mediated Control of STAT5 ActivityThe International Journal of Cell Cloning, 2013
- Deletions of the RUNX2 gene are present in about 10% of individuals with cleidocranial dysplasiaHuman Mutation, 2010
- Functional Analysis of RUNX2 Mutations in Japanese Patients with Cleidocranial Dysplasia Demonstrates Novel Genotype-Phenotype CorrelationsAmerican Journal of Human Genetics, 2002
- Mutations in theRUNX2 gene in patients with cleidocranial dysplasiaHuman Mutation, 2002
- A natural history of cleidocranial dysplasiaAmerican Journal of Medical Genetics, 2001
- Genetic mapping of cleidocranial dysplasia and evidence of a microdeletion in one familyHuman Molecular Genetics, 1995